GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » 3-Year Dividend Growth Rate

Gilead Sciences (BUE:GILD) 3-Year Dividend Growth Rate : 3.30% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences 3-Year Dividend Growth Rate?

Gilead Sciences's Dividends per Share for the three months ended in Dec. 2023 was ARS67.69.

The historical rank and industry rank for Gilead Sciences's 3-Year Dividend Growth Rate or its related term are showing as below:

BUE:GILD' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.3   Med: 8.5   Max: 20.9
Current: 3.3

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Gilead Sciences was 20.90% per year. The lowest was 3.30% per year. And the median was 8.50% per year.

BUE:GILD's 3-Year Dividend Growth Rate is ranked worse than
62.93% of 321 companies
in the Drug Manufacturers industry
Industry Median: 9.1 vs BUE:GILD: 3.30

During the past 12 months, Gilead Sciences's average Dividends Per Share Growth Rate was 2.70% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 3.30% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Gilead Sciences's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.11. As of today, Gilead Sciences's Dividend Yield % is 2.44%.

Good Sign:

Gilead Sciences Inc stock dividend yield is close to 10-year high.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Gilead Sciences's 3-Year Dividend Growth Rate

For the Drug Manufacturers - General subindustry, Gilead Sciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's 3-Year Dividend Growth Rate falls into.



Gilead Sciences 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Gilead Sciences  (BUE:GILD) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Gilead Sciences's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=67.688/ 620.92
=0.11

During the past 13 years, the highest Dividend Payout Ratio of Gilead Sciences was 0.78. The lowest was 0.11. And the median was 0.48.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Gilead Sciences Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
USD 0.1932024-03-142024-03-152024-03-28Cash DividendquarterlyUSD:ARS 842.500000
USD 0.1882023-12-142023-12-152023-12-28Cash DividendquarterlyUSD:ARS 361.000000
USD 0.1882023-09-142023-09-152023-09-28Cash DividendquarterlyUSD:ARS 349.950012
USD 0.1882023-06-142023-06-152023-06-29Cash DividendquarterlyUSD:ARS 240.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Gilead Sciences's Dividend Yield (%) for Today is calculated as

Dividend Yield %=Most Recent Full Year Dividend/Current Share Price
=341.381102256/17621.50
=1.94 %

Current Share Price is ARS17621.50.
Gilead Sciences's Dividends per Share for the trailing twelve months (TTM) ended in Today is ARS341.381102256.

During the past 13 years, the highest Dividend Yield of Gilead Sciences was 4.90%. The lowest was 0.36%. And the median was 3.50%.

Good Sign:

Gilead Sciences Inc stock dividend yield is close to 10-year high.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences 3-Year Dividend Growth Rate Related Terms>


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.